Many targeted cancer therapies suppress T cell immune responses

(The Wistar Institute) New research from The Wistar Institute demonstrated that dozens of these targeted therapies suppressed the activity of T cells that could actually help fight tumors. While studying the FDA-approved targeted therapy trametinib, the researchers also found that pairing it with a signaling protein 'superagonist' stimulated T cell activity while preserving the cancer-blocking effects of the cancer treatment.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

CONCLUSION: Powerful strategies able to selectively interfere with its expression and function should reveal helpful in the development of new anti-cancer therapies. PMID: 30652649 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
After pioneering a targeted cancer therapy, he oversaw MD Anderson in Houston as it gained a reputation as the nation ’ s top cancer hospital.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Mendelsohn, John Deaths (Obituaries) University of Texas M D Anderson Cancer Center Erbitux (Drug) ImClone Systems Inc Source Type: news
Eli Lilly and Co said its cancer treatment Lartruvo failed to meet the main goal in a late-stage trial and it expects to take a charge in the first quarter of 2019, sending its shares down more than 2 percent in early trade.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
A study by UCLA researchers is the first to demonstrate a technique for coaxing pluripotent stem cells — which can give rise to every cell type in the body and which can be grown indefinitely in the lab — into becoming mature T cells capable of killing tumor cells.The technique uses structures called artificial thymic organoids, which work by mimicking the environment of the thymus, the organ in which T cells develop from blood stem cells.T cells are cells of the immune system that fight infections, but also have the potential to eliminate cancer cells. The ability to create them from self-renewing pluripotent ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
CONCLUSIONS Our study reveals that RTHF-mediated inhibition of DUBs and proteasome may provide a potential strategy for cancer therapy. PMID: 30643111 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
With advances in cancer therapy, diseases that were once fatal are becoming chronic disorders, often with adverse endocrine effects.Medscape Diabetes &Endocrinology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news
Cancer therapy decisions are often made according to the histopathological-molecular profile of tumor tissue obtained from surgery or biopsy. It has been shown that tumor profiles change with time and treatment, and that tumor tissue is heterogeneous. Thus, other approaches that are easily accessible and less invasive than surgery or biopsy to monitor responses to treatment and predict relapses are urgently needed. In the last few years, the term “liquid biopsies” has been introduced to represent multifunctional circulating biomarkers in the peripheral blood and other physiological fluids of patients with cance...
Source: Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 16 January 2019Source: Materials Science and Engineering: CAuthor(s): Catarina A. Reis, Carolina F. Rodrigues, André F. Moreira, Telma A. Jacinto, Paula Ferreira, Ilídio J. CorreiaAbstractCancer is one of the major world public health problems and the currently available treatments are nonspecific and ineffective. This reality highlights the importance of developing novel therapeutic approaches. In this field, multifunctional nanomedicines have the potential to revolutionize the currently available treatments. These unique nanodevices can simultaneously act as therapeutic an...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
(Natural News) It has been 16 years since the human genome was decoded — an accomplishment that scientists hoped would someday prove useful in cancer therapy. There was an optimistic, if not naive, belief that we could simply “switch off” cancer-causing genes. Nevertheless, oncologists are still encountering problems with this concept more than a decade...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
r Robert Lukowski Several tumor entities have been reported to overexpress KCa3.1 potassium channels due to epigenetic, transcriptional, or post-translational modifications. By modulating membrane potential, cell volume, or Ca2+ signaling, KCa3.1 has been proposed to exert pivotal oncogenic functions in tumorigenesis, malignant progression, metastasis, and therapy resistance. Moreover, KCa3.1 is expressed by tumor-promoting stroma cells such as fibroblasts and the tumor vasculature suggesting a role of KCa3.1 in the adaptation of the tumor microenvironment. Combined, this features KCa3.1 as a candidate target for inn...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy